Introduction
Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease with a prevalence of 1.8-3% of the population [20] . In RA, the synovial tissue is invaded by inflammatory cells. These leukocytes and their products play an essential role in synovitis, pannus formation and, eventually, joint destruction [20] . Cytokines are mediators involved in the inflammatory events underlying RA [15, 33] . The chemokine family consists of a number of distinct cytokines with structural homology. These proteins have potent chemotactic activity for cells of the immune system, and they appear to play a particularly important role in both the destructive and the fibrovasculoproliferative phase of RA (reviewed in [34, 35, 45, 62, 65, 71] ). Among cells present in the RA synovium, macrophages are a major source of chemokines [34, 35, 45] . Many of these chemokines are also involved in RA-associated angiogenesis, the formation of new blood vessels in the inflamed synovium (reviewed in [63] ).
Clinical management of RA is often difficult, and includes long-term use of immunosuppressants. There are constant attempts to target specific points of the complex pathogenetic network underlying RA, including anti-cytokine therapy.
Here we give a general introduction to chemokines (Table 1) , followed by an overview of the most important chemokines that may play a role in RA. The chemokine interleukin (IL)-8 serves as prototype, since it has been studied most extensively in arthritis. We also discuss recent data on the possible role of certain chemokine receptors in RA (Table 2) . We then summarize the role of chemokines in context with other cytokines present in the RA synovium. Finally, we also give an overview on the clinical importance of chemokines by summarizing experimental data on anti-chemokine targeting in arthritis.
